DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators
•
0 likes•81 views
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AvidBiotics today announced the publication of new fin...
Report
Share
Report
Share
Download to read offline
Recommended
Creative Biolabs-CAMouse™-Fully Human Antibody Generation Platform
This document describes Creative Biolabs' CAMouse fully human antibody generation platform. The CAMouse platform uses transgenic mouse strains that have had their endogenous antibody genes silenced and replaced with human antibody genes, allowing for the generation of fully human antibodies. The document outlines the advantages of the CAMouse platform, including highly efficient gene introduction, fully human antibody sequences, and an excellent mouse immune system for generating antibodies. It also describes the different CAMouse transgenic mouse strains and the processes of hybridoma, phage display, and B cell sorting that can be used for antibody discovery and development on the platform.
Biosafety Testing Solutions for Cell & Gene Therapy
This document discusses biosafety testing for cell and gene therapies performed by BioReliance, a testing services division of Merck KGaA. It outlines the comprehensive testing performed at various stages of development, including testing of cell banks, viral vectors, and final drug products. Testing evaluates important product attributes like identity, purity, potency and residuals to ensure safety and quality. A wide range of assays are used to characterize products and identify potential contaminants.
New technologies for manufacturing recombinant products in embryonated eggs
New non-GMO vector technologies for expressing recombinant proteins in hen eggs offer a novel development and production platform for biologics and vaccines. By upgrading egg-based manufacturing, these technologies bring a wealth of experience and resources to the 21st Century fight against emerging diseases. The AdCEV(TM) vector technology developed by AfriVax and the Sendai Virus vector technologies can potentially improve manufacturing in eggs by increasing yields, expanding the repertoire of possible products, and increasing biosafety. With AdCEV(TM) technology, eggs can be used as miniature bioreactors for rapidly manufacturing a wide range of high-value biopharmaceuticals. The speed with which recombinant products can be developed, scaled and manufactured with these technologies offers a unique competitive advantage compared to other industrial technologies like cell culture and plants.
Industrial manufacturing of vaccines
The document describes the industrial manufacturing process for vaccines. It involves upstream and downstream processes. Upstream involves selecting a seed strain, propagating microorganisms through cell culture or eggs, and isolating/purifying the microorganisms. Downstream involves inactivating organisms, formulating the vaccine, and performing quality control tests. An example of hepatitis B vaccine production using recombinant yeast is provided, involving strain selection, fermentation, antigen expression, purification, and formulation. Potential challenges discussed include vaccine hesitancy, ethical issues, inadequate preclinical data, and the need for new development techniques.
Virus like-particles-based-vaccine-development-services
Virus-like Particles (VLPs) Based Vaccine, an approach that fights viruses with its own weapon, is one of the most exciting emerging vaccine technologies for generating effective and long-lasting protection. https://www.creative-biolabs.com/vaccine/virus-like-particles-based-vaccines.htm
ATCC Zika Virus Research Materials Flyer
ATCC is supporting Zika virus research efforts, such as vaccine efficacy testing and the development of detection assays, with an expanding collection of Zika virus reference materials and solutions, to include:
• In vivo and tissue-culture-adapted strains
• Genomic and synthetic nucleic acid preparations
• Host cell lines and reagents
• Custom solutions for expansion, titering, and banking
Viruses and vaccine production
viral vaccine production basics and manufacturing basics involved in development in research. Cell lines and characteristics of cell substrates and mode of operation useful for increased cell density. Basics of vaccine types and their features.
Virus Like Particles
Virus-like particles (VLPs) are non-infectious nanoparticles that resemble viruses but lack the viral genome. They are formed through the self-assembly of viral structural proteins. VLPs mimic the structure of viruses and can effectively deliver antigens and stimulate immune responses, making them a promising platform for vaccine development. VLP vaccines in clinical trials include ones against HPV, malaria, influenza, and HIV. VLPs can also be used to deliver therapeutic proteins to cells for applications such as cancer treatment.
Recommended
Creative Biolabs-CAMouse™-Fully Human Antibody Generation Platform
This document describes Creative Biolabs' CAMouse fully human antibody generation platform. The CAMouse platform uses transgenic mouse strains that have had their endogenous antibody genes silenced and replaced with human antibody genes, allowing for the generation of fully human antibodies. The document outlines the advantages of the CAMouse platform, including highly efficient gene introduction, fully human antibody sequences, and an excellent mouse immune system for generating antibodies. It also describes the different CAMouse transgenic mouse strains and the processes of hybridoma, phage display, and B cell sorting that can be used for antibody discovery and development on the platform.
Biosafety Testing Solutions for Cell & Gene Therapy
This document discusses biosafety testing for cell and gene therapies performed by BioReliance, a testing services division of Merck KGaA. It outlines the comprehensive testing performed at various stages of development, including testing of cell banks, viral vectors, and final drug products. Testing evaluates important product attributes like identity, purity, potency and residuals to ensure safety and quality. A wide range of assays are used to characterize products and identify potential contaminants.
New technologies for manufacturing recombinant products in embryonated eggs
New non-GMO vector technologies for expressing recombinant proteins in hen eggs offer a novel development and production platform for biologics and vaccines. By upgrading egg-based manufacturing, these technologies bring a wealth of experience and resources to the 21st Century fight against emerging diseases. The AdCEV(TM) vector technology developed by AfriVax and the Sendai Virus vector technologies can potentially improve manufacturing in eggs by increasing yields, expanding the repertoire of possible products, and increasing biosafety. With AdCEV(TM) technology, eggs can be used as miniature bioreactors for rapidly manufacturing a wide range of high-value biopharmaceuticals. The speed with which recombinant products can be developed, scaled and manufactured with these technologies offers a unique competitive advantage compared to other industrial technologies like cell culture and plants.
Industrial manufacturing of vaccines
The document describes the industrial manufacturing process for vaccines. It involves upstream and downstream processes. Upstream involves selecting a seed strain, propagating microorganisms through cell culture or eggs, and isolating/purifying the microorganisms. Downstream involves inactivating organisms, formulating the vaccine, and performing quality control tests. An example of hepatitis B vaccine production using recombinant yeast is provided, involving strain selection, fermentation, antigen expression, purification, and formulation. Potential challenges discussed include vaccine hesitancy, ethical issues, inadequate preclinical data, and the need for new development techniques.
Virus like-particles-based-vaccine-development-services
Virus-like Particles (VLPs) Based Vaccine, an approach that fights viruses with its own weapon, is one of the most exciting emerging vaccine technologies for generating effective and long-lasting protection. https://www.creative-biolabs.com/vaccine/virus-like-particles-based-vaccines.htm
ATCC Zika Virus Research Materials Flyer
ATCC is supporting Zika virus research efforts, such as vaccine efficacy testing and the development of detection assays, with an expanding collection of Zika virus reference materials and solutions, to include:
• In vivo and tissue-culture-adapted strains
• Genomic and synthetic nucleic acid preparations
• Host cell lines and reagents
• Custom solutions for expansion, titering, and banking
Viruses and vaccine production
viral vaccine production basics and manufacturing basics involved in development in research. Cell lines and characteristics of cell substrates and mode of operation useful for increased cell density. Basics of vaccine types and their features.
Virus Like Particles
Virus-like particles (VLPs) are non-infectious nanoparticles that resemble viruses but lack the viral genome. They are formed through the self-assembly of viral structural proteins. VLPs mimic the structure of viruses and can effectively deliver antigens and stimulate immune responses, making them a promising platform for vaccine development. VLP vaccines in clinical trials include ones against HPV, malaria, influenza, and HIV. VLPs can also be used to deliver therapeutic proteins to cells for applications such as cancer treatment.
Production and purification of Viral vectors for gene and cell therapy appli...
Production and purification of Viral vectors for gene and cell therapy appli...Dr. Priyabrata Pattnaik
The cell and gene therapy market is growing rapidly and is projected to reach $10 billion in 5 years. There are three main segments: gene therapy, stem cell therapy, and cell immunotherapy. Gene therapy uses viral vectors like lentivirus or adenovirus to deliver nucleic acids. The production of viral vectors like AAV involves growing HEK 293 cells in bioreactors, transfecting them with plasmids, harvesting and purifying the virus through clarification, filtration, and chromatography. CAR-T cell therapy is also discussed as an example of cell immunotherapy, which uses lentivirus to modify patient T-cells that are then reintroduced to the patient.Production and Purification of Virus Like Particle (VLP) based Vaccine
This document summarizes a presentation on the production and purification of virus-like particle (VLP) based vaccines. It discusses using hepatitis C VLPs as a model system produced using an insect cell/baculovirus expression platform. Key points covered include:
- Challenges in VLP vaccine production include low yields, stability issues, and difficulties removing baculovirus.
- Hepatitis C VLPs containing E1 and E2 glycoproteins were successfully produced using Sf9 insect cells in a Mobius 3L disposable bioreactor, with comparable results to a glass bioreactor.
- A depth filtration clarification process achieved around 70% DNA clearance while recovering approximately 70
Technovax Presentation @ Influenza Congress USA 2012
TechnoVax is developing novel Virus-Like Particle (VLP) vaccines using a cell-based manufacturing system that is safer, more effective, and scalable compared to traditional egg-based vaccine production. Their VLP technology is being used to develop vaccines for influenza, respiratory syncytial virus (RSV), and other diseases. Their influenza VLP vaccines include seasonal tetravalent and "universal" versions. They are seeking partnerships to advance their preclinical vaccine candidates into clinical trials.
Ingenza BILS 2016
Ingenza Ltd is an industrial biotechnology company in Edinburgh, UK that provides synthetic biology and bioprocess development services to chemical, therapeutics, and academic customers. It has capabilities in strain construction, protein engineering, fermentation up to 2L scale, and process development. A key technology is its proprietary inABLE assembly method that allows combinatorial assembly of up to 10 DNA fragments in a single reaction. Ingenza has applied inABLE and screening techniques to optimize pathways and expression for clients. It also operates cGMP compliant facilities for production of biologics in microbial and mammalian hosts.
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Applications of crispr cas system
CRISPR-Cas is a genome editing technique derived from bacterial immune systems that allows for precise genomic modifications. The document discusses applications of CRISPR-Cas in plants, animals, and bacteria, including developing pest and disease resistant crops and livestock, modifying stem cells and embryos, targeting antibiotic resistant bacteria, and controlling gene expression.
dkNET Webinar "YCharOS: Antibody Characterization Through Open Science" 10/22...
Abstract
Many (most!) genes/proteins linked to disease phenotypes remain severely understudied [1]. Distinct open-science initiatives are needed to promote the exploration of currently understudied proteins, from the proper identification of research reagents [2], to the development of a chemical probes for every human protein [1]. We focus on the proper characterization of antibodies to guide researchers in selecting the most specific/selective antibodies for their needed application(s) [3].
Antibodies are among the most commonly used reagents in cell biology. Generally, scientists purchase antibodies from commercial suppliers, and rely on the vendor’s quality control data to make their purchasing decisions. While there are many outstanding commercially-available antibodies, many other antibodies do not perform as advertised - and in the absence of an objective means to compare performance, it is impossible to tell one from the other. This is a widely known problem that plagues tens of thousands of scientists annually [4-6].
There is a scientific solution, enabled by CRISPR/Cas9 technology. By comparing signals from wild-type and isogenic knockout cells, one can readily test the specificity of antibodies. We applied this approach in a pilot study demonstrating that only three of the 16 commercially-available antibodies for C9ORF72, the protein product of a major amyotrophic lateral sclerosis disease locus, specifically recognized the protein. Distressingly, neither antibody had been used in a publication, and the antibody used most frequently in publications, which have been cited thousands of times, did not recognize the protein in any application [7].
We are now applying our antibody characterization pipeline to generate head-to-head comparisons of commercial antibodies for all human proteins. This work is performed in partnership with high-quality manufacturers that provide in-kind reagents (i.e. antibodies and knock-out lines). Finalized antibody characterization reports are progressively uploaded on a free open-science repository (https://zenodo.org/communities/ycharos/). We believe our initiative, Antibody Characterization through Open Science (YCharOS), will contribute to make science more reproducible and help illuminate the dark genome.
The top 3 key questions that YCharOS can answer:
1. Do antibodies used in my field perform as advertised?
2. How do I identify the best performing antibody for my protein of interest?
3. Do I need to launch an expensive and time-consuming antibody generation study or do effective commercial antibodies already exist for my protein of interest?
References (see https://dknet.org/about/blog/2334)
Presenter: Carl Laflamme, PhD, Senior Postdoctoral Fellow at the Montreal Neurological Institute (The Neuro, McGill University). Chetan Raina, YCharOS, CEO.
Upcoming webinars schedule: https://dknet.org/about/webinar
Novartis BILS 2016
The document describes an optimized cell line development platform developed by Novartis. Key aspects include:
1) Implementation of a folic acid receptor selection system and enhanced CHO host cell line to increase productivity of cell pools and clones. This reduced development timelines by 5 months.
2) Evaluation of additional technologies like optimized UTRs/signal peptides and a "monoclonality checker" to further improve the platform.
3) Continuous optimization efforts including screening the CHO transcriptome, generating cell lines lacking problematic genomic regions, and evaluating new vector/selection marker combinations to maximize performance.
Cataloging computationally putative resistance genes in grape and
1. The document discusses a bioinformatics project to catalog computationally putative resistance genes in grape and their corresponding pathogenicity genes.
2. The project searches databases to find main pathogenicity genes in pathogens and resistance genes in Arabidopsis thaliana, then catalogs them and uses BLAST to search for matches in grape genomes.
3. Examples show matches found between the rpfF gene in Xylella fastidiosa and the virB2 gene in Agrobacterium tumefaciens when BLASTed against grape genomes.
dkNET Webinar: Addgene, The Nonprofit Plasmid Repository 04/24/2020
Abstract
Addgene’s mission is to accelerate research and discovery by improving access to useful research materials and information. We facilitate the sharing of high-quality scientific materials, research reproducibility, and open science by archiving and distributing DNA-based research reagents and associated data to scientists worldwide. Our repository contains over 84,000 plasmids, including special collections on CRISPR and fluorescent proteins, and more than 450 ready-to-use AAV and lentiviral preparations. There is no cost for scientists to deposit plasmids, which saves time and money associated with shipping plasmids themselves. All plasmids in Addgene’s repository were deposited by your scientific colleagues from around the world. All plasmids are fully sequenced for validation and sequencing data is openly available. Furthermore, we offer free educational resources about molecular biology topics including the AAV Data Hub, our blog, eBooks, and written and video protocols.
The top 3 key questions that Addgene repository can answer:
1. How can I find relevant DNA-based reagents for studying my disease model of interest?
2. Which molecular biology tools and techniques are appropriate for my experiments?
3. What are the benefits of sharing my plasmids and how do I deposit plasmids into the repository?
Presenter: Dr. Angela Abitua, Outreach Scientist at Addgene, the nonprofit plasmid repository
dkNET Webinar Information: https://dknet.org/about/webinar
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
EMBL grants exclusive license for synthetic baculoviral genomes to Geneva Bio...
EMBL granted Geneva Biotech an exclusive license for synthetic baculoviral genomes created by EMBL researcher Imre Berger. Baculoviruses are commonly used to produce proteins but their genomes are unstable at large scale, reducing protein yields. Berger developed "SynBac" genomes that removed unstable regions to create viruses that maintain high protein expression levels even after multiple amplifications for large-scale production. The new technology licensed by Geneva Biotech has the potential to transform large-scale production of biologics for pharmaceutical applications.
Analytical testing services
Analytical testing service provides deep analysis of samples through biological, chemical and physical methods or high-tech instruments to accurately and rapidly detect trace contamination in products like microbes, viruses, adventitious cells and reagents. The document discusses services for detecting host cell proteins, residual DNA, next generation sequencing, and transmission electron microscopy to identify contamination which can be a major problem in manufacturing biological and clinical products.
Virus Safety in Vaccine Production
Presentation at DCVMN & Merck Advanced Workshop on "Bioprocess Optimization" at Singapore, 7-8 Feb 2018.
Emerging Clinical Applications of CRISPR-Cas9 as Promising Strategies in Gene...
CRISPR/Cas9 gene editing shows promise for correcting diseases through gene therapy and targeted changes. Current applications include editing T-cells to produce CAR T-cells for cancer therapy and editing retinal cells in rats to treat retinitis pigmentosa. Additional areas of focus include eliminating HIV from cells, correcting the Fah mutation in mice, and overcoming issues like delivery efficiency and off-target effects. Looking ahead, cell therapies and local treatments for eye/ear diseases appear promising applications for CRISPR's precise gene editing capabilities.
BILS 2015 Genethon M. Hebben
BILS 2015 Genethon
"Debottlenecking Downstream Process of AAV9 Gene Therapy Vectors using Customized Chromatography Resin"
Matthias Hebben, Ph.D. Bioprocess Development
Plant-produced subviral HBV particles as carriers for antigen protein epitope...
Presentation of a scientific research project - expression of a fusion proteins in plants - carrier structure for immunogenic epitopes, for the purpose of oral vaccine, but also for potential purification and traditional vaccine.
Poster based hcv
This document discusses the development of polymer-based nanoadjuvants for a hepatitis C virus (HCV) vaccine. It first provides background on vaccines and adjuvants, describing common adjuvants like Freund's complete adjuvant. It then discusses nanoparticles made from polymers like poly lactic-co-glycolic acid (PLGA), which are biodegradable and can effectively encapsulate antigens. One study showed PLGA nanoparticles encapsulating HCV proteins enhanced cellular immunity in mice. The document notes challenges to an HCV vaccine like genetic diversity between virus strains, but suggests surface-modified polymeric nanoparticles may help optimize drug release and targeting to improve vaccine delivery.
Bridging The Valley Of Death A Tale Of Two Cultures
This document discusses the challenges of transitioning biotechnology discoveries from research to commercial products, known as crossing the "valley of death". It notes that on average only 1 in 4 to 1 in 5 biotechnology products in development achieve approval due to fundamental differences between the cultures of research and product development. Bridging this gap requires addressing regulatory, capital, and project management challenges throughout the product development process. The future of biotechnology will rely on rigorous project planning, outsourcing, earlier consideration of development pathways, and continual engagement between research and development teams.
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...Diego Alberto Tamayo
Create a system to track the temperature of vaccine using Smart IoT Edge
devices, Smart IoT cloud Eco Systems, Blockchain and Smart Analytics from
manufacturing to storage to transport to consumption – Reduce Wastage and
Improve distribution and lower Inventory!One-Stop Antibody Drug Discovery Services from GenScript ProBio
GenScript ProBio is the biopharmaceutical division of GenScript, a leading biotech company. GenScript ProBio provides end-to-end services from drug discovery to commercialization, including antibody discovery and development, cell line development, process development, and clinical manufacturing. Key services include antibody humanization, developability assessment, and affinity maturation to improve antibody candidates for preclinical and clinical development.
MAKING HEALTHCARE MORE ACCESSIBLE
Dyadic International presented on their C1 vaccine technology platform. C1 is a genetically engineered fungal strain that can rapidly produce high yields of proteins for vaccines and biologics. C1 offers advantages over other platforms like CHO cells, including lower production costs, faster production timelines, and the ability to produce various vaccine modalities. Dyadic discussed their rapid strain development process, high productivity data for vaccine antigens, and plans to initiate a Phase 1 clinical trial of their C1-produced COVID-19 booster vaccine called DYAI-100.
More Related Content
What's hot
Production and purification of Viral vectors for gene and cell therapy appli...
Production and purification of Viral vectors for gene and cell therapy appli...Dr. Priyabrata Pattnaik
The cell and gene therapy market is growing rapidly and is projected to reach $10 billion in 5 years. There are three main segments: gene therapy, stem cell therapy, and cell immunotherapy. Gene therapy uses viral vectors like lentivirus or adenovirus to deliver nucleic acids. The production of viral vectors like AAV involves growing HEK 293 cells in bioreactors, transfecting them with plasmids, harvesting and purifying the virus through clarification, filtration, and chromatography. CAR-T cell therapy is also discussed as an example of cell immunotherapy, which uses lentivirus to modify patient T-cells that are then reintroduced to the patient.Production and Purification of Virus Like Particle (VLP) based Vaccine
This document summarizes a presentation on the production and purification of virus-like particle (VLP) based vaccines. It discusses using hepatitis C VLPs as a model system produced using an insect cell/baculovirus expression platform. Key points covered include:
- Challenges in VLP vaccine production include low yields, stability issues, and difficulties removing baculovirus.
- Hepatitis C VLPs containing E1 and E2 glycoproteins were successfully produced using Sf9 insect cells in a Mobius 3L disposable bioreactor, with comparable results to a glass bioreactor.
- A depth filtration clarification process achieved around 70% DNA clearance while recovering approximately 70
Technovax Presentation @ Influenza Congress USA 2012
TechnoVax is developing novel Virus-Like Particle (VLP) vaccines using a cell-based manufacturing system that is safer, more effective, and scalable compared to traditional egg-based vaccine production. Their VLP technology is being used to develop vaccines for influenza, respiratory syncytial virus (RSV), and other diseases. Their influenza VLP vaccines include seasonal tetravalent and "universal" versions. They are seeking partnerships to advance their preclinical vaccine candidates into clinical trials.
Ingenza BILS 2016
Ingenza Ltd is an industrial biotechnology company in Edinburgh, UK that provides synthetic biology and bioprocess development services to chemical, therapeutics, and academic customers. It has capabilities in strain construction, protein engineering, fermentation up to 2L scale, and process development. A key technology is its proprietary inABLE assembly method that allows combinatorial assembly of up to 10 DNA fragments in a single reaction. Ingenza has applied inABLE and screening techniques to optimize pathways and expression for clients. It also operates cGMP compliant facilities for production of biologics in microbial and mammalian hosts.
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Applications of crispr cas system
CRISPR-Cas is a genome editing technique derived from bacterial immune systems that allows for precise genomic modifications. The document discusses applications of CRISPR-Cas in plants, animals, and bacteria, including developing pest and disease resistant crops and livestock, modifying stem cells and embryos, targeting antibiotic resistant bacteria, and controlling gene expression.
dkNET Webinar "YCharOS: Antibody Characterization Through Open Science" 10/22...
Abstract
Many (most!) genes/proteins linked to disease phenotypes remain severely understudied [1]. Distinct open-science initiatives are needed to promote the exploration of currently understudied proteins, from the proper identification of research reagents [2], to the development of a chemical probes for every human protein [1]. We focus on the proper characterization of antibodies to guide researchers in selecting the most specific/selective antibodies for their needed application(s) [3].
Antibodies are among the most commonly used reagents in cell biology. Generally, scientists purchase antibodies from commercial suppliers, and rely on the vendor’s quality control data to make their purchasing decisions. While there are many outstanding commercially-available antibodies, many other antibodies do not perform as advertised - and in the absence of an objective means to compare performance, it is impossible to tell one from the other. This is a widely known problem that plagues tens of thousands of scientists annually [4-6].
There is a scientific solution, enabled by CRISPR/Cas9 technology. By comparing signals from wild-type and isogenic knockout cells, one can readily test the specificity of antibodies. We applied this approach in a pilot study demonstrating that only three of the 16 commercially-available antibodies for C9ORF72, the protein product of a major amyotrophic lateral sclerosis disease locus, specifically recognized the protein. Distressingly, neither antibody had been used in a publication, and the antibody used most frequently in publications, which have been cited thousands of times, did not recognize the protein in any application [7].
We are now applying our antibody characterization pipeline to generate head-to-head comparisons of commercial antibodies for all human proteins. This work is performed in partnership with high-quality manufacturers that provide in-kind reagents (i.e. antibodies and knock-out lines). Finalized antibody characterization reports are progressively uploaded on a free open-science repository (https://zenodo.org/communities/ycharos/). We believe our initiative, Antibody Characterization through Open Science (YCharOS), will contribute to make science more reproducible and help illuminate the dark genome.
The top 3 key questions that YCharOS can answer:
1. Do antibodies used in my field perform as advertised?
2. How do I identify the best performing antibody for my protein of interest?
3. Do I need to launch an expensive and time-consuming antibody generation study or do effective commercial antibodies already exist for my protein of interest?
References (see https://dknet.org/about/blog/2334)
Presenter: Carl Laflamme, PhD, Senior Postdoctoral Fellow at the Montreal Neurological Institute (The Neuro, McGill University). Chetan Raina, YCharOS, CEO.
Upcoming webinars schedule: https://dknet.org/about/webinar
Novartis BILS 2016
The document describes an optimized cell line development platform developed by Novartis. Key aspects include:
1) Implementation of a folic acid receptor selection system and enhanced CHO host cell line to increase productivity of cell pools and clones. This reduced development timelines by 5 months.
2) Evaluation of additional technologies like optimized UTRs/signal peptides and a "monoclonality checker" to further improve the platform.
3) Continuous optimization efforts including screening the CHO transcriptome, generating cell lines lacking problematic genomic regions, and evaluating new vector/selection marker combinations to maximize performance.
Cataloging computationally putative resistance genes in grape and
1. The document discusses a bioinformatics project to catalog computationally putative resistance genes in grape and their corresponding pathogenicity genes.
2. The project searches databases to find main pathogenicity genes in pathogens and resistance genes in Arabidopsis thaliana, then catalogs them and uses BLAST to search for matches in grape genomes.
3. Examples show matches found between the rpfF gene in Xylella fastidiosa and the virB2 gene in Agrobacterium tumefaciens when BLASTed against grape genomes.
dkNET Webinar: Addgene, The Nonprofit Plasmid Repository 04/24/2020
Abstract
Addgene’s mission is to accelerate research and discovery by improving access to useful research materials and information. We facilitate the sharing of high-quality scientific materials, research reproducibility, and open science by archiving and distributing DNA-based research reagents and associated data to scientists worldwide. Our repository contains over 84,000 plasmids, including special collections on CRISPR and fluorescent proteins, and more than 450 ready-to-use AAV and lentiviral preparations. There is no cost for scientists to deposit plasmids, which saves time and money associated with shipping plasmids themselves. All plasmids in Addgene’s repository were deposited by your scientific colleagues from around the world. All plasmids are fully sequenced for validation and sequencing data is openly available. Furthermore, we offer free educational resources about molecular biology topics including the AAV Data Hub, our blog, eBooks, and written and video protocols.
The top 3 key questions that Addgene repository can answer:
1. How can I find relevant DNA-based reagents for studying my disease model of interest?
2. Which molecular biology tools and techniques are appropriate for my experiments?
3. What are the benefits of sharing my plasmids and how do I deposit plasmids into the repository?
Presenter: Dr. Angela Abitua, Outreach Scientist at Addgene, the nonprofit plasmid repository
dkNET Webinar Information: https://dknet.org/about/webinar
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
EMBL grants exclusive license for synthetic baculoviral genomes to Geneva Bio...
EMBL granted Geneva Biotech an exclusive license for synthetic baculoviral genomes created by EMBL researcher Imre Berger. Baculoviruses are commonly used to produce proteins but their genomes are unstable at large scale, reducing protein yields. Berger developed "SynBac" genomes that removed unstable regions to create viruses that maintain high protein expression levels even after multiple amplifications for large-scale production. The new technology licensed by Geneva Biotech has the potential to transform large-scale production of biologics for pharmaceutical applications.
Analytical testing services
Analytical testing service provides deep analysis of samples through biological, chemical and physical methods or high-tech instruments to accurately and rapidly detect trace contamination in products like microbes, viruses, adventitious cells and reagents. The document discusses services for detecting host cell proteins, residual DNA, next generation sequencing, and transmission electron microscopy to identify contamination which can be a major problem in manufacturing biological and clinical products.
Virus Safety in Vaccine Production
Presentation at DCVMN & Merck Advanced Workshop on "Bioprocess Optimization" at Singapore, 7-8 Feb 2018.
Emerging Clinical Applications of CRISPR-Cas9 as Promising Strategies in Gene...
CRISPR/Cas9 gene editing shows promise for correcting diseases through gene therapy and targeted changes. Current applications include editing T-cells to produce CAR T-cells for cancer therapy and editing retinal cells in rats to treat retinitis pigmentosa. Additional areas of focus include eliminating HIV from cells, correcting the Fah mutation in mice, and overcoming issues like delivery efficiency and off-target effects. Looking ahead, cell therapies and local treatments for eye/ear diseases appear promising applications for CRISPR's precise gene editing capabilities.
BILS 2015 Genethon M. Hebben
BILS 2015 Genethon
"Debottlenecking Downstream Process of AAV9 Gene Therapy Vectors using Customized Chromatography Resin"
Matthias Hebben, Ph.D. Bioprocess Development
Plant-produced subviral HBV particles as carriers for antigen protein epitope...
Presentation of a scientific research project - expression of a fusion proteins in plants - carrier structure for immunogenic epitopes, for the purpose of oral vaccine, but also for potential purification and traditional vaccine.
Poster based hcv
This document discusses the development of polymer-based nanoadjuvants for a hepatitis C virus (HCV) vaccine. It first provides background on vaccines and adjuvants, describing common adjuvants like Freund's complete adjuvant. It then discusses nanoparticles made from polymers like poly lactic-co-glycolic acid (PLGA), which are biodegradable and can effectively encapsulate antigens. One study showed PLGA nanoparticles encapsulating HCV proteins enhanced cellular immunity in mice. The document notes challenges to an HCV vaccine like genetic diversity between virus strains, but suggests surface-modified polymeric nanoparticles may help optimize drug release and targeting to improve vaccine delivery.
Bridging The Valley Of Death A Tale Of Two Cultures
This document discusses the challenges of transitioning biotechnology discoveries from research to commercial products, known as crossing the "valley of death". It notes that on average only 1 in 4 to 1 in 5 biotechnology products in development achieve approval due to fundamental differences between the cultures of research and product development. Bridging this gap requires addressing regulatory, capital, and project management challenges throughout the product development process. The future of biotechnology will rely on rigorous project planning, outsourcing, earlier consideration of development pathways, and continual engagement between research and development teams.
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...Diego Alberto Tamayo
Create a system to track the temperature of vaccine using Smart IoT Edge
devices, Smart IoT cloud Eco Systems, Blockchain and Smart Analytics from
manufacturing to storage to transport to consumption – Reduce Wastage and
Improve distribution and lower Inventory!What's hot (20)
Production and purification of Viral vectors for gene and cell therapy appli...
Production and purification of Viral vectors for gene and cell therapy appli...
Production and Purification of Virus Like Particle (VLP) based Vaccine
Production and Purification of Virus Like Particle (VLP) based Vaccine
Technovax Presentation @ Influenza Congress USA 2012
Technovax Presentation @ Influenza Congress USA 2012
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
dkNET Webinar "YCharOS: Antibody Characterization Through Open Science" 10/22...
dkNET Webinar "YCharOS: Antibody Characterization Through Open Science" 10/22...
Cataloging computationally putative resistance genes in grape and
Cataloging computationally putative resistance genes in grape and
dkNET Webinar: Addgene, The Nonprofit Plasmid Repository 04/24/2020
dkNET Webinar: Addgene, The Nonprofit Plasmid Repository 04/24/2020
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
EMBL grants exclusive license for synthetic baculoviral genomes to Geneva Bio...
EMBL grants exclusive license for synthetic baculoviral genomes to Geneva Bio...
Emerging Clinical Applications of CRISPR-Cas9 as Promising Strategies in Gene...
Emerging Clinical Applications of CRISPR-Cas9 as Promising Strategies in Gene...
Plant-produced subviral HBV particles as carriers for antigen protein epitope...
Plant-produced subviral HBV particles as carriers for antigen protein epitope...
Bridging The Valley Of Death A Tale Of Two Cultures
Bridging The Valley Of Death A Tale Of Two Cultures
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...
Similar to DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators
One-Stop Antibody Drug Discovery Services from GenScript ProBio
GenScript ProBio is the biopharmaceutical division of GenScript, a leading biotech company. GenScript ProBio provides end-to-end services from drug discovery to commercialization, including antibody discovery and development, cell line development, process development, and clinical manufacturing. Key services include antibody humanization, developability assessment, and affinity maturation to improve antibody candidates for preclinical and clinical development.
MAKING HEALTHCARE MORE ACCESSIBLE
Dyadic International presented on their C1 vaccine technology platform. C1 is a genetically engineered fungal strain that can rapidly produce high yields of proteins for vaccines and biologics. C1 offers advantages over other platforms like CHO cells, including lower production costs, faster production timelines, and the ability to produce various vaccine modalities. Dyadic discussed their rapid strain development process, high productivity data for vaccine antigens, and plans to initiate a Phase 1 clinical trial of their C1-produced COVID-19 booster vaccine called DYAI-100.
Accelerate innovation and manufacturing in cell and gene therapy.pptx
The rapid expansion of the gene and cell therapy pipeline created constraints to accessing contract capacities around the globe. Innovation in gene and cell therapy expanded many drug development pipelines, and startups that are lacking internal production capacities heavily rely on contract manufacturing organizations (CDMO).
Biosecurity Challenges in the Genome Engineering Space – Beth Vitalis
A presentation by Beth Vitalis, Biosecurity Specialist at Inscripta, on "Biosecurity Challenges in the Genome Engineering Space."
Bio outsource services
BioOutsource is a company that provides testing services for biologics and vaccines to ensure quality and safety. They offer a unique combination of scientific expertise and innovative IT solutions embedded in a GMP-compliant environment. Services include cell-based assays for safety and potency testing of vaccines and biologics, molecular biology techniques like PCR for virus detection and residual DNA testing, and analytical protein tests. All services are performed according to GMP standards using validated methods. Client documentation and test results are securely stored and accessible through their web-based system.
PEGS Boston the essential protein engineering summit
With record-breaking attendance in 2015, PEGS Boston attracts an international delegation of nearly 2,000 participants including conference delegates, speakers, exhibitors, sponsors and guests representing over 30 countries.
Participants value the in-depth short courses, access to 22 conferences, and wide-ranging presentations delivering new unpublished data, case studies, innovation and insight.
The vast exhibit hall will be packed with 125 exhibiting companies and more than 200 research posters on display providing valuable viewing of innovative new technologies, as well as abundant networking with biopharma researchers and industry representatives.
Creative BioMart expands its recombinant proteins products portfolio
Creative BioMart has expanded its portfolio of recombinant protein products to cover more genes and species. Recombinant proteins are proteins encoded by recombinant DNA that has been inserted into a host cell, allowing for large-scale expression of exogenous genes. Creative BioMart has provided over 100,000 recombinant proteins covering most genes. Their portfolio includes proteins from multiple species and expression systems, with various tags and as full-length or fragmented proteins. Creative BioMart aims to offer recombinant proteins that closely mimic the natural state of proteins with high purity levels.
Microbion_nutraceuticals_emailing
Microbion offers analytical, research and development, and bio-bank services for nutraceutical companies. Their services include genomic analysis of microorganisms used in probiotics and fermented foods, as well as assessing genetic stability, purity, safety, and validating health claims. Microbion can also authenticate strains using DNA fingerprinting and develop diagnostic methods and protocols tailored for specific customer strains or formulations.
What You May Have Missed at AACC 2018 White Paper - Kalorama Information
Each year the American Association for Clinical Chemistry draws tens of thousands of lab professionals and in vitro diagnostic vendors to one place. Kalorama Information was there and noted major developments at the meeting in this White Paper. Major themes of scientific sessions, new products from lab and IVD vendors are included.
Applied Biosystems: Products, Technologies, Future Innovations, Impact on Gen...
Applied Biosystems: Products, Technologies, Future Innovations, Impact on Gen...The Lifesciences Magazine
Key Products and Technologies of Applied Biosystems: 1. DNA Sequencing Instruments 2. Real-Time PCR Systems 3. Next-Generation Sequencing (NGS) 4. Capillary Electrophoresis APPLICATIONS of Biotechnology
Biotechnology is the use of living organisms to develop useful products. Modern biotechnology techniques include isolating DNA, inserting genes into vectors, and transforming host cells. Applications include producing Bt crops for pest resistance, producing vaccines and diagnosing diseases. New advances include artificial lymph nodes, non-invasive cancer detection from saliva, smart contact lenses to monitor eye pressure, and machines that can scan the liver non-invasively. Biotechnology continues to progress rapidly with applications in agriculture, medicine, and other fields.
PEGS China 2015 Final Agenda
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
Leveraging Neo4j to Create a Sustainable Partnership-Based Metagenomic Supply...
Basecamp Research leverages Neo4j to create a sustainable partnership-based metagenomic supply chain for the bioeconomy. They provide biodiversity guardians with an equitable way to share environmental genomic data with biotechnology innovators to power the bioeconomy. They combine deep learning, a graph infrastructure, and contextual understanding to predict protein functions, features, and properties from microbial dark matter. They link provenance, biochemistry, and industrial applications by attaching relevant metadata to genomic data to make it usable for protein discovery and annotating proteins with useful information.
Emerging Trends in Biotechnology.pptx
This document discusses emerging trends in biotechnology, including artificial intelligence, big data, gene editing, precision medicine, gene sequencing, biomanufacturing, synthetic biology, bioprinting, microfluidics, and tissue engineering. It explains how these trends are enabling biotechnology startups to develop new medical products and therapies, scale operations, drive innovation, offer personalized treatment, and optimize bioprocessing. Gene editing techniques in particular allow for targeted gene modification and applications in gene therapy and transgenic organisms.
Paradigm Change in Biomanufacturing
- Biopharmaceutical manufacturing is undergoing a paradigm shift from unique, specialized production of individual products to more uniform, systematic production that can apply to multiple products. This increases manufacturing efficiency and the number of products that can be produced.
- Contract manufacturing is increasing and promises to open the pipeline for new biopharmaceuticals by reducing costs for innovators and increasing availability of products. Using contract manufacturers reduces financial risks for originators.
- Technological convergence has standardized cell culture and purification processes, allowing "one facility fits all" manufacturing that regulatory agencies now accept for contract manufacturing. This reduces costs and speeds development and availability of new products.
darpa documents
The Defense Advanced Research Projects Agency (DARPA) recently renewed an $8 million grant over two years for a team led by the University of Maryland, Baltimore County's (UMBC's) Center for Advanced Sensor Technology (CAST). The team is developing a portable briefcase-sized device that can produce therapeutic proteins like insulin within a few hours in small batches. This would be critical in situations where medical supply lines are disrupted, such as in war zones or after natural disasters. The device works by using cellular extracts from Chinese hamster ovarian cells and DNA to produce the desired protein within 2-4 hours. The next steps are purification and polishing to remove impurities. The team will validate that the produced proteins have similar purity
CMS presentation 10.21.2020 es
Mapping the key safety considerations, risk assessments, and testing recommendations for cultivated meat manufacturing
Cell Therapy Industry News Round-Up - September 13, 2022 [BioInformant]
The document discusses several topics related to stem cells and regenerative medicine:
1) It provides an overview of 10 scientists nominated for a $100,000 stem cell research grant to be awarded in October.
2) It describes a new collaboration between RoosterBio and AGC Biologics to accelerate manufacturing of cell and exosome therapies.
3) It announces that Steakholder Foods will begin developing cultured pork products using induced pluripotent stem cells.
Phage panning
Library Construction and Screening
Fig.1 Workflow of phage display construction
and screening (Díez et al. 2015)
Phage display is one of the most powerful and widely used laboratory technique for the study of protein-protein, protein-peptide and protein-DNA interactions. This technology is mainly based on displaying the interest protein (peptides, antibodies, scaffolds or others) on the surface of employing phage and then be used to interrogate the constructed libraries containing millions or even billions of displayed phages. Theoretically, phage display is an exogenous gene expression method which the gene encoding the interest protein is inserted into bacteriophage coat protein gene then displaying the interest protein on the phage surfaces, resulting in a connection between genotype and phenotype.
Phage panning
Creative Biolabs has long-term devoted to the development and application of phage display technology. With years of experience, our scientists have developed several phage display based platforms and tailored hundreds of particular libraries and thousands of specific antibody products to boost our global customers’ research and project goals. We are pleased to use our extensive experience and advanced platform to offer the best service and the most qualified products to satisfy each demand from our customers.
Similar to DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators (20)
One-Stop Antibody Drug Discovery Services from GenScript ProBio
One-Stop Antibody Drug Discovery Services from GenScript ProBio
Accelerate innovation and manufacturing in cell and gene therapy.pptx
Accelerate innovation and manufacturing in cell and gene therapy.pptx
Biosecurity Challenges in the Genome Engineering Space – Beth Vitalis
Biosecurity Challenges in the Genome Engineering Space – Beth Vitalis
PEGS Boston the essential protein engineering summit
PEGS Boston the essential protein engineering summit
Creative BioMart expands its recombinant proteins products portfolio
Creative BioMart expands its recombinant proteins products portfolio
What You May Have Missed at AACC 2018 White Paper - Kalorama Information
What You May Have Missed at AACC 2018 White Paper - Kalorama Information
Applied Biosystems: Products, Technologies, Future Innovations, Impact on Gen...
Applied Biosystems: Products, Technologies, Future Innovations, Impact on Gen...
Leveraging Neo4j to Create a Sustainable Partnership-Based Metagenomic Supply...
Leveraging Neo4j to Create a Sustainable Partnership-Based Metagenomic Supply...
Cell Therapy Industry News Round-Up - September 13, 2022 [BioInformant]
Cell Therapy Industry News Round-Up - September 13, 2022 [BioInformant]
DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators
- 1. DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AvidBiotics today announced the publication of new findings in PLoS Genetics that could enable genetic machinery used by many bacteria and bacteriophages to quickly adapt to ever-changing conditions to be harnessed for a variety of protein engineering applications. The publication by company co-founder Jeff F. Miller, Ph.D. and his colleagues at the University of California, Los Angeles, and AvidBiotics, defines the DNA sequences and structures that allow Diversity Generating Retroelements (DGRs) to mutate DNA sequences to direct changes ("diversification") at specific locations in a protein molecule. This technology enables the rapid generation of highly diverse libraries of protein scaffolds for use in the creation of novel therapeutic and prophylactic drugs, diagnostics and binding reagents. "DGRs offer a competitive advantage to many bacteria and bacteriophages in nature, as they allow them to quickly adapt and survive under challenging conditions," said Dr. Miller. "The typical DGR can theoretically generate more than 10 trillion diverse genetic sequences at select sites in target genes. Thus, DGRs can potentially be used to generate molecular diversity for protein engineering applications that are not practical with currently available technologies. "Our new publication not only describes new mechanistic information about DGRs, but it also offers a blueprint for the use of DGRs in protein engineering," Dr. Miller concluded.
- 2. AvidBiotics, which has worldwide rights to the DGR technology, is working to apply this technology to both its product development platforms, as well as leverage its value through collaborations and licensing arrangements. The Diversity Generating Retro-element (DGR) System is well suited for a variety of protein engineering applications, offering such advantages as: No need for repeated cycles of cloning and transformation as in phage display Mutagenesis "homes in" on specific amino acid positions of interest, not random ones, in the target protein A host bacterium does all the diversification "naturally" Diversification can be serially and cumulatively repeated without degeneration of the genetic mechanism or the protein scaffold In addition to providing a tool for use with AvidBiotics' targeted antibacterial and antiviral/anti- cancer product platforms, the DGR system could be applied to:
- 3. Protein engineering by optimizing or modifying particular sites of interest, applicable to any scaffold Generation of highly specific protein diagnostics to detect most any "analyte" Generation of reagents for product recovery processes Creation of kits and reagents for research laboratory use in protein engineering About AvidBiotics AvidBiotics is a developer of novel, non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancers. The scaffolds of AvidBiotics' proteins exhibit functional potency, e.g. killing, exceeding that of antibodies. AvidBiotics has two proprietary product platforms. The first is a new class of tailorable, targeted bactericidal agents for use in the treatment or prevention of specific bacterial infections. The second specifically flags virus-infected or cancerous cells for enhanced destruction by the Natural Killer and T cells of the potent innate immunity system. AvidBiotics focuses on human therapeutic applications of its technologies, both on its own and in partnership with governmental agencies and research institutions, while taking advantage of further near-term collaborative opportunities offered by specific applications of its products and technology platforms in areas such as food safety, biodefense and animal husbandry. For more information on AvidBiotics, please visit the company's web site at http://www.avidbiotics.com.